Weak 1Q At AstraZeneca, CEO Quits
AstraZeneca (NYSE:AZN) reported first quarter 2012 core adjusted earnings of $1.81 per American Depositary Share (ADS), 4 cents below the Zacks Consensus Estimate. Earnings were down 19% (at constant exchange rates [CER]) year over year. Higher tax rate hurt earnings during the quarter. AstraZeneca’s quarterly revenues fell 11% (at CER) year over year to $7.3 [...]
AstraZeneca (NYSE:AZN) reported first quarter 2012 core adjusted earnings of $1.81 per American Depositary Share (ADS), 4 cents below the Zacks Consensus Estimate. Earnings were down 19% (at constant exchange rates [CER]) year over year. Higher tax rate hurt earnings during the quarter.
AstraZeneca’s quarterly revenues fell 11% (at CER) year over year to $7.3 billion, owing to intense generic competition. Revenues were much below the Zacks Consensus Estimate of $7.9 billion.
All growth rates … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards